The global stem cells market size was estimated to be USD 14.56 billion in 2023 and is expected to reach at USD 40.80 billion by 2034 with a CAGR of 9.82% during the forecast period 2024-2034. Rising emphasis on the development of precision medicine, an increase in the number of cell therapy manufacturing facilities, a growing number of clinical trial procedures, increased demand for stem cell banking, a rise in research endeavors concerning the production, storage, and characterization of stem cells, technological improvements, a rise in the number of older people, a growing need for regenerative medicines to aid in early disease detection and prevention, an increase in market player funding, an increase in government initiatives, and a surge in the development of induced pluripotent stem cell (iPSC) technology, which has significantly advanced the fields of stem cell biology and regenerative medicine.
Surge in advancements in Induced Pluripotent Stem Cell (iPSC) technology have significantly contributed to the fields of stem cell biology & regenerative medicine is predicted to boost the market growth during the forecast period. iPSCs, derived from adult somatic cells, undergo reprogramming to attain pluripotency similar to Embryonic Stem Cells (ESCs). Notably, ESCs are obtained through the destruction of embryos at the blastocyst stage, leading to ethical concerns. In contrast, iPSCs involve genetic reprogramming of somatic cells, avoiding the ethical dilemma associated with embryo destruction in research. This ethical advantage has propelled market growth and expanded the applications of iPSC technology, including disease modeling, drug discovery, and the development of cell therapies. For instance, in June 2023, FUJIFILM Cellular Dynamics, a leading manufacturer of human induced pluripotent stem cells (iPSCs), has introduced the human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit. This kit, designed for scientists engaged in drug discovery for neuroactive drugs, features enhanced barrier integrity. It holds the potential to propel advancements in drug discovery, development, and medical research, particularly for disorders affecting the Central Nervous System (CNS).
By product, adult stem cells was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the progression of cell banking services and advancements in the fields of bio preservation & cryopreservation, reduced ethical concerns associated with the use of adult cells, the utilization of Mesenchymal Stem Cells (MSCs) in autologous transplantation, significant clinical trials showcasing their efficacy in treating various diseases, ongoing extensive research to explore further therapeutic applications, and rising launch of new products. For instance, in July 2023, PromoCell has unveiled the 'PromoExQ MSC Growth Medium XF,' specifically designed for cell therapy manufacturing applications. This xeno- and serum-free medium adheres to the company's EXCiPACT GMP certification scheme. Optimized for in-vitro expansion of human Mesenchymal Stem Cells (MSCs) in a GMP-regulated environment, the medium ensures consistent growth and maintenance of various types of multipotent MSCs. Additionally, induced pluripotent stem cells is predicted to grow at fastest CAGR during the forecast period owing to Heightened investment in the development of regenerative medicines using induced pluripotent stem cells, with a focus on ensuring reproducibility and maintenance, their capacity to differentiate into all cell types, and their high proliferative ability, numerous prominent companies are expanding their services related to iPSCs.
By technology, cell acquisition was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the increasing research & development activities, growing awareness regarding bone marrow harvest, surge in prevalence of blood cancer, convenient availability of bone marrow transplantation therapy, and rising collaborations within market players. For instance, in April 2022, STEMCELL Technologies Canada has entered into a collaboration with Applied Cells to provide an effective cell separation solution. This collaboration combines STEMCELL's EasySep immunomagnetic cell separation kits with Applied Cells' MARS platform. The integration of these technologies aims to offer researchers worldwide an automated and enhanced method for isolating high-quality cells from various sample types, including bone marrow, whole blood, apheresis products, and dissociated tissue. Additionally, is predicted to grow at fastest CAGR during the forecast period owing to the rapid advances in cellular therapy research and growing demand for in vitro fertilization (IVF) procedures.
By therapy, allogenic therapy was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the increase in pricing & an expansion within the stem cell banking industry, several cell therapy companies are transitioning their focus towards the development of allogeneic cell therapy products, increasing strategic initiatives by key market players to enhance and fortify their product portfolios. For instance, in June 2022, Bristol Myers Squibb (BMS) and Immatics are set to collaborate on the development of up to seven cancer cell therapies, building upon a three-year-old collaboration initiated by BMS's predecessor, Celgene. Under this new partnership, BMS and Immatics will jointly develop two programs owned by BMS, while retaining options to collaborate on up to four additional programs each. The project will make use of BMS-developed technologies along with Immatics' allogeneic Adoptive Cell Therapy (ACT) platform, known as ACTallo. Additionally, autologous therapy is predicted to grow at fastest CAGR during the forecast period owing to the advantages of autologous therapy include low risk of side effects, affordability, and enhanced patient survival rates, elimination of the need for identifying an HLA-matched donor, and the absence of graft-versus-host diseases, and increasing adoption of autologous MSCs in regenerative medicine.
By application, regenerative medicine was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the surge in approvals for clinical trials involving stem cell therapies aimed at addressing diverse diseases, rising investment by governments for the advancement of regenerative medicines. Additionally, drug discovery & development is predicted to grow at fastest CAGR during the forecast period as it proves valuable in exploring the etiology of human diseases, identifying pathological mechanisms, devising therapeutic strategies to address a range of illnesses, and growing regulatory approvals. For instance, in April 2023, The U.S. FDA has approved Gamida Cell's allogeneic cell treatment, Omisirge (omidubicel-onlv), for use in treating hematologic malignancies in adult and pediatric patients 12 years of age and older. The approval is grounded in the results of a global and randomized Phase 3 clinical study, marking Omisirge as the first allogeneic stem cell transplant therapy to achieve such recognition.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the growing prevalence of chronic disease, rising clinical trials, increase in strategic initiatives coupled with enhancements in healthcare services, and surge in regulatory approvals. For instance, in April 2022, The U.S. FDA has given clearance to BioCardia's Investigational New Drug (IND) application, allowing the initiation of a Phase I/II clinical trial for BCDA-04 in adults recovering from acute respiratory distress syndrome associated with COVID-19. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for the development of medicines for a variety of ailments is expected to drive industry-academic cooperation. It is likely that government agencies would spearhead the backing of these efforts, and large corporations will likely increase their investments in universities and research facilities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of innovators & major market participants, extensive research & development efforts, the promotion of personalized medicines, increasing governmental efforts to encourage the adoption & development of stem cell therapies, and growing partnerships & collaborations within market players. For instance, in June 2022, STEMCELL Technologies has revealed a supply partnership with PBS Biotech, making the PBS-MINI Bioreactor accessible through STEMCELL Technologies for researchers seeking to scale up their human pluripotent stem cell cultures. The PBS-MINI is designed to be compatible with STEMCELL's TeSR family of 3D suspension culture media, providing a convenient solution for the scale-up of human pluripotent stem cell cultures already established in TeSR media. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of diseases such as cancer, neurological disorders, & diabetes, robust product pipelines for therapies centered on stem cells, coupled with a substantial patient population, and surge in government funding to accelerate research on stem cell. For instance, in February 2022, The Indian government has established state-of-the-art stem cell research facilities in 40 prominent health research and educational institutions. In addition, it has given the Indian Council of Medical Research (ICMR) USD 80 million for specific research projects throughout the preceding three years.
Surge in advancements in Induced Pluripotent Stem Cell (iPSC) technology have significantly contributed to the fields of stem cell biology & regenerative medicine is predicted to boost the market growth during the forecast period. iPSCs, derived from adult somatic cells, undergo reprogramming to attain pluripotency similar to Embryonic Stem Cells (ESCs). Notably, ESCs are obtained through the destruction of embryos at the blastocyst stage, leading to ethical concerns. In contrast, iPSCs involve genetic reprogramming of somatic cells, avoiding the ethical dilemma associated with embryo destruction in research. This ethical advantage has propelled market growth and expanded the applications of iPSC technology, including disease modeling, drug discovery, and the development of cell therapies. For instance, in June 2023, FUJIFILM Cellular Dynamics, a leading manufacturer of human induced pluripotent stem cells (iPSCs), has introduced the human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit. This kit, designed for scientists engaged in drug discovery for neuroactive drugs, features enhanced barrier integrity. It holds the potential to propel advancements in drug discovery, development, and medical research, particularly for disorders affecting the Central Nervous System (CNS).
By product, adult stem cells was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the progression of cell banking services and advancements in the fields of bio preservation & cryopreservation, reduced ethical concerns associated with the use of adult cells, the utilization of Mesenchymal Stem Cells (MSCs) in autologous transplantation, significant clinical trials showcasing their efficacy in treating various diseases, ongoing extensive research to explore further therapeutic applications, and rising launch of new products. For instance, in July 2023, PromoCell has unveiled the 'PromoExQ MSC Growth Medium XF,' specifically designed for cell therapy manufacturing applications. This xeno- and serum-free medium adheres to the company's EXCiPACT GMP certification scheme. Optimized for in-vitro expansion of human Mesenchymal Stem Cells (MSCs) in a GMP-regulated environment, the medium ensures consistent growth and maintenance of various types of multipotent MSCs. Additionally, induced pluripotent stem cells is predicted to grow at fastest CAGR during the forecast period owing to Heightened investment in the development of regenerative medicines using induced pluripotent stem cells, with a focus on ensuring reproducibility and maintenance, their capacity to differentiate into all cell types, and their high proliferative ability, numerous prominent companies are expanding their services related to iPSCs.
By technology, cell acquisition was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the increasing research & development activities, growing awareness regarding bone marrow harvest, surge in prevalence of blood cancer, convenient availability of bone marrow transplantation therapy, and rising collaborations within market players. For instance, in April 2022, STEMCELL Technologies Canada has entered into a collaboration with Applied Cells to provide an effective cell separation solution. This collaboration combines STEMCELL's EasySep immunomagnetic cell separation kits with Applied Cells' MARS platform. The integration of these technologies aims to offer researchers worldwide an automated and enhanced method for isolating high-quality cells from various sample types, including bone marrow, whole blood, apheresis products, and dissociated tissue. Additionally, is predicted to grow at fastest CAGR during the forecast period owing to the rapid advances in cellular therapy research and growing demand for in vitro fertilization (IVF) procedures.
By therapy, allogenic therapy was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the increase in pricing & an expansion within the stem cell banking industry, several cell therapy companies are transitioning their focus towards the development of allogeneic cell therapy products, increasing strategic initiatives by key market players to enhance and fortify their product portfolios. For instance, in June 2022, Bristol Myers Squibb (BMS) and Immatics are set to collaborate on the development of up to seven cancer cell therapies, building upon a three-year-old collaboration initiated by BMS's predecessor, Celgene. Under this new partnership, BMS and Immatics will jointly develop two programs owned by BMS, while retaining options to collaborate on up to four additional programs each. The project will make use of BMS-developed technologies along with Immatics' allogeneic Adoptive Cell Therapy (ACT) platform, known as ACTallo. Additionally, autologous therapy is predicted to grow at fastest CAGR during the forecast period owing to the advantages of autologous therapy include low risk of side effects, affordability, and enhanced patient survival rates, elimination of the need for identifying an HLA-matched donor, and the absence of graft-versus-host diseases, and increasing adoption of autologous MSCs in regenerative medicine.
By application, regenerative medicine was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the surge in approvals for clinical trials involving stem cell therapies aimed at addressing diverse diseases, rising investment by governments for the advancement of regenerative medicines. Additionally, drug discovery & development is predicted to grow at fastest CAGR during the forecast period as it proves valuable in exploring the etiology of human diseases, identifying pathological mechanisms, devising therapeutic strategies to address a range of illnesses, and growing regulatory approvals. For instance, in April 2023, The U.S. FDA has approved Gamida Cell's allogeneic cell treatment, Omisirge (omidubicel-onlv), for use in treating hematologic malignancies in adult and pediatric patients 12 years of age and older. The approval is grounded in the results of a global and randomized Phase 3 clinical study, marking Omisirge as the first allogeneic stem cell transplant therapy to achieve such recognition.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global stem cells market in 2023 owing to the growing prevalence of chronic disease, rising clinical trials, increase in strategic initiatives coupled with enhancements in healthcare services, and surge in regulatory approvals. For instance, in April 2022, The U.S. FDA has given clearance to BioCardia's Investigational New Drug (IND) application, allowing the initiation of a Phase I/II clinical trial for BCDA-04 in adults recovering from acute respiratory distress syndrome associated with COVID-19. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for the development of medicines for a variety of ailments is expected to drive industry-academic cooperation. It is likely that government agencies would spearhead the backing of these efforts, and large corporations will likely increase their investments in universities and research facilities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of innovators & major market participants, extensive research & development efforts, the promotion of personalized medicines, increasing governmental efforts to encourage the adoption & development of stem cell therapies, and growing partnerships & collaborations within market players. For instance, in June 2022, STEMCELL Technologies has revealed a supply partnership with PBS Biotech, making the PBS-MINI Bioreactor accessible through STEMCELL Technologies for researchers seeking to scale up their human pluripotent stem cell cultures. The PBS-MINI is designed to be compatible with STEMCELL's TeSR family of 3D suspension culture media, providing a convenient solution for the scale-up of human pluripotent stem cell cultures already established in TeSR media. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of diseases such as cancer, neurological disorders, & diabetes, robust product pipelines for therapies centered on stem cells, coupled with a substantial patient population, and surge in government funding to accelerate research on stem cell. For instance, in February 2022, The Indian government has established state-of-the-art stem cell research facilities in 40 prominent health research and educational institutions. In addition, it has given the Indian Council of Medical Research (ICMR) USD 80 million for specific research projects throughout the preceding three years.
Segmentation: Stem Cells Market Report 2023 - 2034
Stem Cells Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Very Small Embryonic Like Stem Cells
- Induced Pluripotent Stem Cells (iPSCs)
- Human Embryonic Stem Cells (HESCs)
- Adult Stem Cells (ASCs)
- Neural
- Mesenchymal
- Hematopoietic
- Epithelial/Skin
- Others
Stem Cells Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Cryopreservation
- Expansion & Sub-Culture
- Cell Acquisition
- Apheresis
- Umbilical Blood Cord
- Bone Marrow Harvest
- Cell Production
- Isolation
- Cell Culture
- In-vitro Fertilization
- Therapeutic Cloning
Stem Cells Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Allogenic
- Autologous
Stem Cells Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery & Development
- Regenerative Medicine
- Cardiovascular and Myocardial Infraction
- Neurology
- Incontinence
- Oncology
- Orthopedics
- Diabetes
- Injuries
- Hematology
- Liver Disorder
- Others
Stem Cells Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospitals & Cell Banks
Stem Cells Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Stem Cells Market: Product Estimates & Trend Analysis
8. Stem Cells Market: Technology Estimates & Trend Analysis
9. Stem Cells Market: Therapy Estimates & Trend Analysis
10. Stem Cells Market: Application Estimates & Trend Analysis
11. Stem Cells Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Stem Cells Market
14. Europe Global Stem Cells Market
15. Asia Pacific Global Stem Cells Market
16. Latin America Global Stem Cells Market
17. MEA Global Stem Cells Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Osiris Therapeutics
- Advanced Cell Technology Inc.
- CellGenix GmbH
- Kite Pharma
- Tigenix
- PromoCell GmbH
- Brainstorm Cell Therapeutics
- Cellartis AB
- STEMCELL Technologies Inc.
- Celgene Corporation
- Gamida Cell
- Lonza
- Genea Biocells
- Bioheart Inc.
- Cellular Engineering Technologies Inc.
- Angel Biotechnology
- Caladrius Biosciences
- Waisman Biomanufacturing
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 14.56 Billion |
| Forecasted Market Value ( USD | $ 40.8 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
